Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) reported Q4 EPS of ($1.31), $0.07 better than the analyst estimate of ($1.38). Revenue for the quarter came in at $13.08 million versus the consensus estimate of $5.29 million.

For earnings history and earnings-related data on Tarsus Pharmaceuticals, Inc. (TARS) click here.